Search / Trial NCT06227195

Mechanism of IL-10 Pathway-mediated Regulatory B Cell Dysfunction in Osteoarthritis

Launched by SHUFENG LI · Jan 18, 2024

Trial Information

Current as of October 07, 2024

Completed

Keywords

Description

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:Patients who met the American College of Rheumatology diagnostic criteria for OA
  • -
  • Exclusion Criteria:
  • * Patients with trauma, other forms of arthritis such as rheumatoid arthritis, psoriatic arthritis or spondyloarthritis, and other active inflammatory diseases

About Shufeng Li

Shufeng Li is a distinguished clinical trial sponsor dedicated to advancing medical research and innovative therapies. With a strong commitment to improving patient outcomes, the organization specializes in the design and execution of clinical trials across various therapeutic areas. Shufeng Li employs a rigorous scientific approach, leveraging cutting-edge methodologies and a collaborative network of healthcare professionals to ensure the highest standards of ethical conduct and compliance. Their focus on transparency, patient safety, and robust data integrity positions them as a trusted partner in the clinical research landscape.

Locations

Jinan, Shandong, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0